VCNX(Delisted)
VaccinexยทNASDAQ
--
--(--)
VCNX Profile
Vaccinex, Inc.
A biotechnology company that develops antibody-based therapies for cancer and neurodegenerative diseases
1895 Mount Hope Avenue, Rochester, New York 14620
--
Vaccinex, Inc., was incorporated in April 2001 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company dedicated to the discovery and development of targeted biotherapeutic drugs to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune diseases. The company is leveraging their SEMA 4D antibody platform and their extensive knowledge in SEMA 4D biology to develop the lead product candidate pepinemab (also known as VX 15/2503). The company focuses on the development of pepinemab for the treatment of certain cancer indications, particularly head and neck squamous cell carcinoma, pancreatic cancer and PDAC, as well as neurodegenerative diseases, including Huntington's disease and Alzheimer's disease.
